CDSCO issues regulatory pathway for R&D of IVD kit for diagnosis of COVID-19
Delhi: Through the recent notice Central Drugs Standard Control Organization(CDSCO), Directorate General of Health Services as apprised about the regulatory pathway for R&D of IVD kit for diagnosis of COVID-19.
Novel Corona-virus Disease (COVID-19) has spread over 118 countries with now more than 191.127 cases and 7807 people have lost their lives as on 18.03.2020. World Health Organization (WHO) has declared it as pandemic. However, there is no current evidence from randomized clinical trials to recommend any specific treatment for suspected or confirmed patients with COVID-19. In order to encourage research & development of in-vitro diagnostic kits for diagnosis of COVID-19, any application submitted to CDSCO will be processed on high priority. CDSCO will also provide guidance on a regulatory pathway on such matters. The details are as under -
1. Any firm having an In-vitro Diagnostic Kit under development for COVID-19 can directly approach DCG(I) through the Public Relations Office for seeking guidance for the regulatory pathways.
2. Any firm having In-vitro Diagnostic Kit already approved for COVID-19 in any other country can directly approach DCG(I) through Public Relations Office regarding expedited review accelerated approval for marketing in India.
3. Data requirement for clinical performance evaluation, etc. may be abbreviated, deferred, or waived on case to case basis depending on the type & nature of the diagnostic kit, existing data on the product and evidence of available clinical performance evaluation data of such kit.
4. Applications to manufacture or import In-vitro Diagnostic Kit for test, evaluation and further use in performance evaluation may be processed on priority within 7 days.
5. Application for conducting performance evaluation and applications to import or manufacture In-vitro Diagnostic Kit for sale and distribution would be processed on priority through the expedited review/accelerated approval
For any additional information contact Public Relations Office through toll-free number 1800 11 1454 & write to email@example.com .
For full details click on the link given below
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here